otenzepad: cardioselective muscarinic receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 107867 |
| CHEMBL ID | 17045 |
| CHEBI ID | 111174 |
| SCHEMBL ID | 341879 |
| MeSH ID | M0139724 |
| Synonym |
|---|
| 11-[2-[2-(diethylaminomethyl)-1-piperidyl]acetyl]-5h-pyrido[2,3-b][1,4]benzodiazepin-6-one |
| 11-((2-((diethylamino)methyl)-1-piperidinyl)acetyl)-5,11-dihydro-6h-pyrido[2,3-b][1,4]benzodiazepin-6-one |
| 6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one, 5,11-dihydro-11-((2-((diethylamino)methyl)-7-piperidinyl)acetyl)- |
| 6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one, 11-((2-((diethylamino)methyl)-1-piperidinyl)acetyl)-5,11-dihydro- |
| brn 4212983 |
| HMS3393L18 |
| HMS3267K08 |
| BRD-A00520476-001-03-3 |
| gtpl309 |
| afdx116 |
| PDSP2_000466 |
| NCI60_022223 |
| otenzepad |
| af-dx 116 |
| af-dx 116 bs |
| PDSP1_000944 |
| nsc664529 |
| nsc-664529 |
| PDSP1_000468 |
| PDSP2_000930 |
| MLS001424139 |
| MLS000758304 |
| 6h-pyrido[2,3-b][1,4]benzodiazepin-6-one, 11-[[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro- [cas] |
| smr000466280 |
| NCGC00025002-02 |
| L023945 |
| CHEBI:111174 |
| HMS2051L18 |
| CHEMBL17045 , |
| 102394-31-0 |
| af-dx-116 |
| 2-diethylaminomethyl-1-[2-oxo-2-(6-oxo-5,6-dihydro-benzo[e]pyrido[3,2-b][1,4]diazepin-11-yl)-ethyl]-piperidinium |
| (af-dx 116) 11-[2-(2-diethylaminomethyl-piperidin-1-yl)-acetyl]-5,11-dihydro-benzo[e]pyrido[3,2-b][1,4]diazepin-6-one |
| 11-[2-(2-diethylaminomethyl-piperidin-1-yl)-acetyl]-5,11-dihydro-benzo[e]pyrido[3,2-b][1,4]diazepin-6-one |
| af-dx 116,(+/-) |
| bdbm50018056 |
| 5-{2-[2-(2-dipropylamino-ethyl)-piperidin-1-yl]-acetyl}-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one |
| 11-[2-[2-(diethylaminomethyl)piperidin-1-yl]acetyl]-5h-pyrido[2,3-b][1,4]benzodiazepin-6-one |
| NCGC00025002-03 |
| cas-102394-31-0 |
| dtxsid0045674 , |
| dtxcid8025674 |
| tox21_110942 |
| CCG-101052 |
| otenzepad [inn] |
| unii-om7j0xal0s |
| om7j0xal0s , |
| 11-[[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6h-pyrido[2,3-b][1,4]benzodiazepin-6-one |
| 6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one, 11-(2-(2-((diethylamino)methyl)-1-piperidinyl)acetyl)-5,11-dihydro- |
| (+/-)-11-((2-((diethylamino)methyl)piperidino)acetyl)-5,11-dihydro-6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one |
| SCHEMBL341879 |
| AKOS022180220 |
| NC00302 |
| NCGC00025002-04 |
| tox21_110942_1 |
| 11-[[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11,-dihydro-6h-pyrido[2,3-b][1,4]benzodiazepin-6-one |
| (-)-11-[[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6h-pyrido[2,3-b][1,4]benzodiazepin-6-one |
| UBRKDAVQCKZSPO-UHFFFAOYSA-N |
| (+)-11-[[2-[(diethylamino)methyl-]-1-piperidinyl]acetyl]-5,11-dihydro-6h-pyrido[2,3-b][1,4]benzodiazepin-6-one |
| 11-(2-(2-((diethylamino)methyl)piperidin-1-yl)acetyl)-5h-benzo[e]pyrido[3,2-b][1,4]diazepin-6(11h)-one |
| afdx-116 |
| c24h31n5o2 |
| HB1501 |
| 11-[[2-[(diethylamino)methyl]-1-pip eridinyl]acetyl]-5,11-dihydro-6h-pyrido[2,3-b][1,4 ]benzodiazepin-6-one |
| 6h-pyrido[2,3-b][1,4]benzodiazepin-6-one,11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro- |
| J-000681 |
| 100158-38-1 |
| sr-01000597383 |
| SR-01000597383-1 |
| unii-ww6a9tfl2c |
| unii-sx2wtg9r3z |
| af-dx-250 |
| otenzepad, (+)- |
| 6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one, 11-((2-((diethylamino)methyl)-1-piperidinyl)acetyl)-5,11-dihydro-, (-)- |
| SX2WTG9R3Z , |
| 6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one, 11-(2-(2-((diethylamino)methyl)-1-piperidinyl)acetyl)-5,11-dihydro-, (+)- |
| otenzepad, (-)- |
| 122467-13-4 |
| 121029-35-4 |
| WW6A9TFL2C , |
| 6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one, 11-((2-((diethylamino)methyl)-1-piperidinyl)acetyl)-5,11-dihydro-, (+)- |
| af-dx 116, >=98% (hplc) |
| 6h-pyrido[2,3-b][1,4]benzodiazepin-6-one, 11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-;6h-pyrido[2,3-b][1,4]benzodiazepin-6-one, 11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro- |
| FT-0762040 |
| z-l-tyrosinemethylester |
| HMS3676I07 |
| Q27088218 |
| HMS3412I07 |
| CS-0021266 |
| HY-101381 |
| F82112 |
| MS-27403 |
| 11-[[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,1 1-dihydro-6h-pyrido[2,3-b][1,4]benzodiazepin-6-one |
| 11-(2-(2-((DIETHYLAMINO)METHYL)PIPERIDIN-1-YL)ACETYL)-5,11-DIHYDRO-6H-BENZO[E]PYRIDO[3,2-B][1,4]DIAZEPIN-6-ONE |
| CEA39431 |
| 6h-pyrido[2,3-b][1,4]benzodiazepin-6-one, 11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro- |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " All these antagonists caused a concentration-dependent rightward shift of the dose-response curve for carbachol-stimulated amylase release without altering the maximal response." | ( Characterization of muscarinic receptor subtypes on rat pancreatic acini: pharmacological identification by secretory responses and binding studies. Kashima, K; Kataoka, K; Kato, M; Kuriyama, K; Ohkuma, S, 1992) | 0.28 |
| " In tissues precontracted with methacholine, 11-([[2-(diethylamino)methyl]-1-piperidinyl]acetyl)5,11- dihydro-6H-pyrido[2,3-6][1,4]benzodiazepine-6-one (AF-DX 116), a selective M2 antagonist, shifted dose-response curves to both isoproterenol and forskolin significantly to the left." | ( M2 muscarinic receptors inhibit isoproterenol-induced relaxation of canine airway smooth muscle. Fernandes, LB; Fryer, AD; Hirshman, CA, 1992) | 0.28 |
| "3 microM) shifted the dose-response curve to the right in a parallel manner." | ( Muscarinic receptor is coupled with a cation channel through a GTP-binding protein in guinea-pig chromaffin cells. Inoue, M; Kuriyama, H, 1991) | 0.28 |
| " Low concentrations of pirenzepine (10(-8) M), produced a rightward shift in the dose-response curve to McN, without inhibiting responses to carbachol." | ( Functional subtyping of muscarinic receptors on canine esophageal mucosa. Donoff, B; Lad, R; Rangachari, PK, 1991) | 0.28 |
| " Alinidine (10(-6) M) shifted the dose-response curves of acetylcholine and carbachol to the right, but it did not affect those for isosorbide dinitrate, isoproterenol and adenosine." | ( Anti-muscarinic effect of alinidine on acetylcholine-induced vasodilation in isolated and perfused dog coronary arteries. Chiba, S; Furukawa, Y; Nakane, T, 1991) | 0.28 |
| " Characteristic dose-response curves for acetylcholine showing greater negative inotropic response with dose were seen." | ( The effects of AF-DX 116, a cardioselective muscarinic antagonist, on the negative inotropic action of acetylcholine. Baskin, SI; Thomsen, RH, 1991) | 0.28 |
| " Dose-response curves were constructed, and the IC50s determined for 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), pirenzepine (PRZ) and 11-2[[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11,-dihydro- 6H-pyrido[2,3-b] [1,4]benzodiazepin-6-one (AF-DX 116) were 72 nM, 385 nM, and 24 microM, respectively." | ( Activation of the pharmacologically defined M3 muscarinic receptor depolarizes hippocampal pyramidal cells. Alger, BE; Pitler, TA, 1990) | 0.28 |
| " All the antagonists shifted the methacholine dose-response curve to the right in a parallel and concentration-dependent fashion, yielding Schild plots with slopes not significantly different from unity." | ( Characterization of the muscarinic receptor subtype involved in phosphoinositide metabolism in bovine tracheal smooth muscle. Elzinga, CR; Meurs, H; Roffel, AF; Zaagsma, J, 1990) | 0.28 |
| " Assuming that the binding of carbachol to one site (Site 1) increases [14C]aminopyrine accumulation but its binding to the other site (Site 2) reduces [14C]aminopyrine accumulation, we analysed the dose-response curves for the carbachol effects in the absence and presence of different concentrations of atropine, pirenzepine and AF-DX 116." | ( Carbachol-induced potentiation and inhibition of acid secretion by guinea pig gastric gland. Haga, T; Honda, N; Ichiyama, A; Kajimura, M; Kaneko, E, 1990) | 0.28 |
| "The dose-response curve for the muscarine-induced depolarisation of the rat isolated superior cervical ganglion, studied over the concentration range of 3 nM-1 mM, was biphasic." | ( Biphasic dose-response curve to muscarine on the rat superior cervical ganglion. Gilbert, MJ; Newberry, NR, 1989) | 0.28 |
| " 4-DAMP, atropine, and pirenzepine caused a progressive parallel rightward shift in the dose-response curve of pancreatic secretion for bethanechol." | ( Subtypes of muscarinic receptors in pancreatic exocrine secretion in anesthetized dog. Chiba, S; Haruta, K; Homma, N; Horiuchi, A; Iwatsuki, K; Yonekura, H, 1989) | 0.28 |
| " Oxotremorine generated dose-response curves that were similar in both the circular and longitudinal vectors and intermediate to those previously reported for carbachol and aceclidine." | ( The effect of muscarinic agonists and selective receptor subtype antagonists on the contractile response of the isolated rhesus monkey ciliary muscle. Gabelt, BT; Kaufman, PL; Poyer, JF, 1994) | 0.29 |
| " Inhibitors of phospholipase C, protein kinase C, calcium/calmodulin, nitric oxide synthase and guanylate cyclase, shifted the dose-response curve of carbachol on contractility to the right." | ( Endogenous nitric oxide signalling system and the cardiac muscarinic acetylcholine receptor-inotropic response. Borda, E; Echagüe, AV; Genaro, A; Leiros, CP; Sterin-Borda, L, 1995) | 0.29 |
| " The dose-response curves of 2-butynyloxy, cyclopropylmethyloxy and hexyloxy compound together was the same as the response of each separately." | ( 1,2,5-Thiadiazole derivatives of arecoline stimulate M1 receptors coupled to phosphoinositide turnover. Hoss, W; Messer, WS; Periyasamy, S; Roknich, S; Sauerberg, P, 1995) | 0.29 |
| " The in vivo dose-response effects of "selective" muscarinic antagonists on changes in lung resistance (RL) and heart rate (HR) in response to electrical stimulation of the vagus nerves were obtained in four groups of newborns." | ( Cardiopulmonary actions of muscarinic receptor subtypes in the newborn dog. Anderson, JW; Brundage, KL; Fisher, JT, 1996) | 0.29 |
| " In the isolated AV node preparation, dose-response curves for negative dromotropic effects (prolongation of Atrio-His interval) of carbachol (CCh) injected into the posterior septal artery were shifted to the right in parallel by AF-DX, pirenzepine, and atropine with apparent pA2-values of 13, 27." | ( Comparison of anti-M2-muscarinic effect of AF-DX 116 on atrioventricular nodal conduction with those of pirenzepine and atropine as antibradyarrhythmic drugs. Motomura, S; Sasaki, S, 1999) | 0.3 |
| Class | Description |
|---|---|
| benzodiazepine | A group of heterocyclic compounds with a core structure containing a benzene ring fused to a diazepine ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 1.1883 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 29.8493 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 14.1254 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | KA | 6.8100 | 0.0110 | 2.2807 | 6.8100 | AID141437 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1090602 | Displacement of [3H]AF-DX 384 from Drosophila melanogaster mAChR by scintillation counting | 2007 | Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6 | Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists. |
| AID142638 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of cuneiform nucleus region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID723862 | Binding affinity to human M3 muscarinic receptor | 2013 | Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4 | Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists. |
| AID142626 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of bed nucleus stria terminalis region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142768 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of periaqueductal region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID1090584 | Toxicity to Musca domestica (house fly) assessed as mortality at 6.25 ug/fly measured after 24 hr | 2007 | Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6 | Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists. |
| AID142644 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of dorsomedial hypothalamus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142778 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of rhomboid thalamic nucleus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142632 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of cerebellum, lobe 3 region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142634 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of cerebral cortex layers I-III of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142798 | Binding affinity to the rat cardiac muscarinic acetylcholine receptor M2 using 0.3 nM [3H]N-methylscopolamine as radioligand | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics. |
| AID142622 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of Primary olfactory cortex region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142753 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of hippocampus CA1 region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142764 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of medial geniculate region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142782 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of superior coliculus, infragranular region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID141606 | Binding affinity for glandular muscarinic acetylcholine receptor M3 in rat assayed using 0.3 nM [3H]N-methylscopolamine as radioligand | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics. |
| AID142767 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of paraventricular thalamic nucleus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142628 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of central gray, pons region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142891 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of ventromedial hypothalamus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID225367 | Binding affinity by the displacement of [3H]NMS binding to muscarinic M2 receptor of rat heart | 1993 | Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1 | Synthesis and structure-activity relationship of some 5-[[[(dialkylamino)alkyl]-1-piperidinyl]acetyl]-10,11-dihydro-5H- benzo[b,e][1,4]diazepin-11-ones as M2-selective antimuscarinics. |
| AID723861 | Binding affinity to human M2 muscarinic receptor | 2013 | Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4 | Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists. |
| AID141734 | Selectivity ratio for glandular muscarinic receptor 3 and cardiac muscarinic receptor 2 in rat | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics. |
| AID142889 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of ventral posterior thalamic nucleus region of brain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142770 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of posterior cingulate cortex region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142779 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of subiculum region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142625 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of basolateral amygdaloid nucleus region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142633 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of cerebellum, lobe 4 region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142866 | Inhibition of muscarinic (M2) receptor isolated from rat atria | 1994 | Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22 | Construction of a molecular shape analysis-three-dimensional quantitative structure-analysis relationship for an analog series of pyridobenzodiazepinone inhibitors of muscarinic 2 and 3 receptors. |
| AID225361 | Binding affinity by the displacement of [3H]NMS binding to A9 L cells transfected with muscarinic M1 receptor of rat brain | 1993 | Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1 | Synthesis and structure-activity relationship of some 5-[[[(dialkylamino)alkyl]-1-piperidinyl]acetyl]-10,11-dihydro-5H- benzo[b,e][1,4]diazepin-11-ones as M2-selective antimuscarinics. |
| AID235335 | Selectivity ratio against M2 and M3 receptors measured in silico | 1994 | Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22 | Construction of a molecular shape analysis-three-dimensional quantitative structure-analysis relationship for an analog series of pyridobenzodiazepinone inhibitors of muscarinic 2 and 3 receptors. |
| AID142777 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of reuniens thalamic nucleus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142771 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of posterior hypothalamus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142762 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of medial amygdaloid nucleus region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142887 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of ventral lateral geniculate region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID141437 | Displacement of [3H]pirenzepine from Muscarinic acetylcholine receptor M1 in rabbit sympathetic ganglia homogenate | 1992 | Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15 | Amide, urea, and carbamate analogues of the muscarinic agent [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride. |
| AID141010 | Inhibition of rat submandibular muscarinic (M3) receptor isolated from tissue homogenates | 1994 | Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22 | Construction of a molecular shape analysis-three-dimensional quantitative structure-analysis relationship for an analog series of pyridobenzodiazepinone inhibitors of muscarinic 2 and 3 receptors. |
| AID142757 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of lateral amygdaloid nucleus region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142775 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of retrospinal cortex region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142780 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of substantia nigra region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID1090585 | Toxicity to Musca domestica (house fly) assessed as mortality at 6.25 ug/fly measured after 2.5 hr | 2007 | Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6 | Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists. |
| AID1090587 | Toxicity to Musca domestica (house fly) assessed as mortality at 6.25 ug/fly measured after 1 hr | 2007 | Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6 | Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists. |
| AID142766 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of neostriatum region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142641 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of dorsal parabrachial nucleus region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142759 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of lateral posterior thalamic nucleus region of mid brain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142774 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of reticular thalamic nucleus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142645 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of entorhinal cortex region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID1090586 | Toxicity to Musca domestica (house fly) assessed as mortality at 6.25 ug/fly measured after 1.5 hr | 2007 | Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6 | Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists. |
| AID142781 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of superior coliculus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142623 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of anterior cingulate cortex region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142639 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of dentate gyrus region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142758 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of lateral dorsal thalamic nucleus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142763 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of medial dorsal thalamic nucleus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142761 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of lateral hypothalamus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142624 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of anterior hypothalamus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142886 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of ventral dentate gyrus region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142627 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of central amygdaloid nucleus region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142643 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of dorsal tegmentum region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142888 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of ventral parabrachial nucleus region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142642 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of dorsal raphe nucleus region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142629 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of central medial thalamic nucleus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142621 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of ventral subiculum region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID723860 | Binding affinity to human M4 muscarinic receptor | 2013 | Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4 | Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists. |
| AID142760 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of lateral septal nucleus of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142755 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of hippocampus CA3 region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142754 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of hippocampus CA2 region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142769 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of pontine nuclei region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142765 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of medial raphe nucleus region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142640 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of dorsal lateral geniculate region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142630 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of cerebellum, lobe 1 region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142772 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of posterior thalamic nucleus region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142631 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of cerebellum, lobe 2 region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142756 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of inferior coliculus region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142892 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of zona inserta region of midbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142637 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of cudate nucleus region of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID723863 | Binding affinity to human M1 muscarinic receptor | 2013 | Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4 | Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists. |
| AID1090588 | Toxicity to Musca domestica (house fly) assessed as mortality at 6.25 ug/fly measured after 0.5 hr | 2007 | Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6 | Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists. |
| AID142635 | Inhibition of binding of [3H]l-quinuclidinyl benzilate ([3H]L-QNB) to muscarinic acetylcholine receptor of cerebral cortex layers IV and V of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID1090601 | Displacement of [3H]QNB from Drosophila melanogaster mAChR by scintillation counting | 2007 | Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6 | Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists. |
| AID142636 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of cerebral cortex layers VI of forebrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID142773 | Inhibition of binding of [3H]L-quinuclidinyl benzilate ([3H]-l-QNB) to muscarinic acetylcholine receptor of raphe pontis region of hindbrain | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6 | Regional differences in the binding of selective muscarinic receptor antagonists in rat brain: comparison with minimum-energy conformations. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1345699 | Rat M3 receptor (Acetylcholine receptors (muscarinic)) | 1992 | Life sciences, , Volume: 51, Issue:12 | Cloning of the rat M3, M4 and M5 muscarinic acetylcholine receptor genes by the polymerase chain reaction (PCR) and the pharmacological characterization of the expressed genes. |
| AID1345326 | Human M2 receptor (Acetylcholine receptors (muscarinic)) | 1989 | Molecular pharmacology, Apr, Volume: 35, Issue:4 | Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. |
| AID1345435 | Rat M4 receptor (Acetylcholine receptors (muscarinic)) | 1992 | Life sciences, , Volume: 51, Issue:12 | Cloning of the rat M3, M4 and M5 muscarinic acetylcholine receptor genes by the polymerase chain reaction (PCR) and the pharmacological characterization of the expressed genes. |
| AID1345364 | Rat M2 receptor (Acetylcholine receptors (muscarinic)) | 1992 | Life sciences, , Volume: 51, Issue:12 | Cloning of the rat M3, M4 and M5 muscarinic acetylcholine receptor genes by the polymerase chain reaction (PCR) and the pharmacological characterization of the expressed genes. |
| AID1345543 | Human M5 receptor (Acetylcholine receptors (muscarinic)) | 1989 | Molecular pharmacology, Apr, Volume: 35, Issue:4 | Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. |
| AID1345189 | Rat M1 receptor (Acetylcholine receptors (muscarinic)) | 1989 | Molecular pharmacology, Apr, Volume: 35, Issue:4 | Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. |
| AID1345343 | Human M3 receptor (Acetylcholine receptors (muscarinic)) | 1989 | Molecular pharmacology, Apr, Volume: 35, Issue:4 | Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. |
| AID1345364 | Rat M2 receptor (Acetylcholine receptors (muscarinic)) | 1998 | The Journal of pharmacology and experimental therapeutics, Feb, Volume: 284, Issue:2 | Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. |
| AID1345189 | Rat M1 receptor (Acetylcholine receptors (muscarinic)) | 1992 | Life sciences, , Volume: 51, Issue:12 | Cloning of the rat M3, M4 and M5 muscarinic acetylcholine receptor genes by the polymerase chain reaction (PCR) and the pharmacological characterization of the expressed genes. |
| AID1345465 | Human M4 receptor (Acetylcholine receptors (muscarinic)) | 1996 | Biochemical pharmacology, Aug-23, Volume: 52, Issue:4 | Stimulation of cyclic AMP accumulation and phosphoinositide hydrolysis by M3 muscarinic receptors in the rat peripheral lung. |
| AID1345286 | Human M1 receptor (Acetylcholine receptors (muscarinic)) | 1996 | Biochemical pharmacology, Aug-23, Volume: 52, Issue:4 | Stimulation of cyclic AMP accumulation and phosphoinositide hydrolysis by M3 muscarinic receptors in the rat peripheral lung. |
| AID1345364 | Rat M2 receptor (Acetylcholine receptors (muscarinic)) | 1988 | The EMBO journal, Oct, Volume: 7, Issue:10 | Cloned M1 muscarinic receptors mediate both adenylate cyclase inhibition and phosphoinositide turnover. |
| AID1345511 | Rat M5 receptor (Acetylcholine receptors (muscarinic)) | 1992 | Life sciences, , Volume: 51, Issue:12 | Cloning of the rat M3, M4 and M5 muscarinic acetylcholine receptor genes by the polymerase chain reaction (PCR) and the pharmacological characterization of the expressed genes. |
| AID1345326 | Human M2 receptor (Acetylcholine receptors (muscarinic)) | 1998 | The Journal of pharmacology and experimental therapeutics, Feb, Volume: 284, Issue:2 | Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 77 (21.63) | 18.7374 |
| 1990's | 217 (60.96) | 18.2507 |
| 2000's | 35 (9.83) | 29.6817 |
| 2010's | 20 (5.62) | 24.3611 |
| 2020's | 7 (1.97) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.02) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (0.27%) | 5.53% |
| Reviews | 7 (1.91%) | 6.00% |
| Case Studies | 1 (0.27%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 358 (97.55%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||